(Total Views: 828)
Posted On: 08/29/2020 1:27:08 PM
Post# of 155730
I’m intrigued as well on Creativ MicroTech, especially on CTCs. Thanks for posting, Techguru.
A couple of additional articles on CTCs in breast and prostate cancer are below.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912467/
For breast cancer, the article summarized the completed and ongoing clinical trials (as of 2019) using CTC number or phenotype for treatment decisions (7 studies). Based on current knowledge, CTCs can be regarded as a useful prognostic and predictive marker that is well suited for both risk stratification and treatment monitoring in breast cancer patients. On the database site ClinicalTrials.gov, 59 studies were retrieved by searching using the keywords “circulating tumor cells” and “breast cancer” at the time the search was performed (end of March 2019).
https://www.medpagetoday.com/meetingcoverage/...lsmm/87147
Medpage article (June 2020) on Prostate cancer discussing a large phase III randomized clinical trial, SWOG S1216, a study run by the NCI Southwest Oncology Group. They obtained baseline CTC counts for men going on trial. the man who had zero CTCs had more than a six-fold odds ratio of having a complete response in terms of a 7-month PSA on hormonal therapy, relative to the man who had five or more CTCs. And conversely, the man who had five or more CTCs had an almost four-fold odds ratio for progression 2 years on therapy relative to the man who had zero CTCs. And these sorts of relationships (statistically significant) held across different cut points.
A couple of additional articles on CTCs in breast and prostate cancer are below.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912467/
For breast cancer, the article summarized the completed and ongoing clinical trials (as of 2019) using CTC number or phenotype for treatment decisions (7 studies). Based on current knowledge, CTCs can be regarded as a useful prognostic and predictive marker that is well suited for both risk stratification and treatment monitoring in breast cancer patients. On the database site ClinicalTrials.gov, 59 studies were retrieved by searching using the keywords “circulating tumor cells” and “breast cancer” at the time the search was performed (end of March 2019).
https://www.medpagetoday.com/meetingcoverage/...lsmm/87147
Medpage article (June 2020) on Prostate cancer discussing a large phase III randomized clinical trial, SWOG S1216, a study run by the NCI Southwest Oncology Group. They obtained baseline CTC counts for men going on trial. the man who had zero CTCs had more than a six-fold odds ratio of having a complete response in terms of a 7-month PSA on hormonal therapy, relative to the man who had five or more CTCs. And conversely, the man who had five or more CTCs had an almost four-fold odds ratio for progression 2 years on therapy relative to the man who had zero CTCs. And these sorts of relationships (statistically significant) held across different cut points.
(5)
(0)
